Theratechnologies Inc T.TH

Deals get done

[scarlet1967]

Deals between Canadian based company and big asian/ global companies gets done so THTX oncology program can attract partners globally. Genevant has offices in BC Canada, US and Switzerland.

 

https://www.genevant.com/contact-us/

 

“Under the terms of the deal, Genevant will receive as much as $303 million in upfront and possible milestone payments, plus royalties on future sales. Takeda will have exclusive access to the former's LNP technology in all phases of development and distribution. Neither of the companies revealed the two types of liver diseases they are targeting with this project.”

 

Genevant, Takeda Enter Collab to Find a Cure for Rare Liver Diseases | BioSpace

 

As per their LNP technology:

“LNPs can provide both optimal uptake into desired cells and efficient release, resulting in functional delivery of nucleic acid payloads to target tissues.”

 

Their first collaboration March 2021:

 

“Under the terms of the agreement, Genevant is initially eligible to receive up to $600 million in upfront and milestone payments, plus royalties on future product sales. Takeda has exclusive rights to Genevant’s LNP technology for a specified number of selected hepatic stellate cells targets.”

 

https://finance.yahoo.com/amphtml/news/genevant-sciences-announces-global-collaboration-120000465.html

[SABBOBCAT]

I was day dreaming on the drive to work this morning and thinking a reverse takeover would be an way for a some of these foreign companies to list in NA. Plus, why not pick up some interesting IP with a niche Montreal based player that is struggling to get appropriate valuation?

[muslix1]

good volume in US ... there is something brewing...

[qwerty22]

Interesting day. Does the after hours action matter?  

[SPCEO1]

Not unless there is serious volume and/or news that is driving the price action.

[qwerty22]

I get more of a sense of thtx tracking the general/biotech indices a little more than it used to. If you put up a comparison chart of the last 3 months it almost perfectly matches the ups and downs of the XBI. I'm tempted to think this is a sign there are more eyes on the stock.

[palinc2000]

I think Paul got a big lesson with the OO,Remember that Paul s background and track record involves almost all aspects of a public company except financing....I think he will perform much better for the next round I am pretty sure that he is taking a very role in expanding the investor base,,,,,He is a BUILDER and not a PATCHER  ,,,,,,